Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
Hum Immunol. 2013 Feb;74(2):256-60. doi: 10.1016/j.humimm.2012.11.003. Epub 2012 Nov 29.
The aims of this study were to identify the candidate causal single nucleotide polymorphisms (SNPs) and candidate causal mechanisms of asthma and to generate SNP to gene to pathway hypotheses.
SNPs that met a threshold of p ≤ 0.001 in a genome-wide association study (GWAS) dataset of asthma, which included 292,443 SNPs in 473 asthma cases and 1892 controls, were used in the present study. Identify candidate causal SNPs and pathway (ICSNPathway) analysis was applied to this dataset.
ICSNPathway analysis identified four candidate causal SNPs, four genes, and 21 candidate causal pathways, which in total provided four hypothetical biologic mechanisms: (1) rs7192 (nonsynonymous coding) to HLA-DRA to 21 pathways, such as, the role of eosinophils in the chemokine network of allergy, Th1/Th2 differentiation, and asthma (nominal p ≤ 0.001, FDR p ≤ 0.01); (2) rs20541 (nonsynonymous coding) to IL13 to asthma and cytokines and inflammatory response (nominal p<0.001, FDR p ≤ 0.008); (3) rs1058808 (frameshift coding) to ERBB2 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01); (4) rs17350764 (nonsynonymous coding (deleterious)) to OR52J3 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01).
By applying ICSNPathway analysis to asthma GWAS data, we found four candidate causal SNPs, four genes involving HLA-DRA and IL-13, and four hypotheses, which may contribute to asthma susceptibility.
本研究旨在鉴定哮喘的候选因果单核苷酸多态性(SNP)和候选因果机制,并提出 SNP 到基因再到通路的假说。
本研究使用了一项哮喘全基因组关联研究(GWAS)数据集的满足 p≤0.001 阈值的 SNP,该数据集包含 292443 个 SNP,其中 473 例哮喘患者和 1892 例对照。采用 ICSNPathway 分析对该数据集进行分析。
ICSNPathway 分析鉴定出了四个候选因果 SNP、四个基因和 21 个候选因果通路,总共提供了四个假设的生物学机制:(1)rs7192(非同义编码)到 HLA-DRA 到 21 个通路,如嗜酸粒细胞在过敏趋化因子网络、Th1/Th2 分化和哮喘中的作用(名义 p≤0.001, FDR p≤0.01);(2)rs20541(非同义编码)到 IL13 到哮喘和细胞因子及炎症反应(名义 p<0.001, FDR p≤0.008);(3)rs1058808(移码编码)到 ERBB2 到跨膜受体活性(名义 p=0.001, FDR p=0.01);(4)rs17350764(非同义编码(有害))到 OR52J3 到跨膜受体活性(名义 p=0.001, FDR p=0.01)。
通过将 ICSNPathway 分析应用于哮喘 GWAS 数据,我们发现了四个候选因果 SNP、涉及 HLA-DRA 和 IL-13 的四个基因以及四个假说,这些可能有助于哮喘易感性。